Question

There is evidence that cytotoxic T lymphocytes (T cells) participate in controlling tumor growth and that they can be harnessed to use the body's immune system to treat cancer. One study investigated the use of a T cell-engaging antibody, blinatumomab, to recruit T cells to control tumor growth. The data below are T cell counts (1000 per microliter) at baseline (beginning of the study) and after 20 days on blinatumomab for 6 subjects in the study. The difference (after 20 days minus baseline) is the response variable.

Baseline	0.04	0.02	0	0.02	0.46	0.36
After 20 days	0.18	0	1.1	0	0	0.34
Difference	0.14	-0.02	1.1	-0.02	-0.46	-0.02

Do the data give evidence at the 5 % level that the mean count of T cells is higher after 20 days on blinatumomab?

The test statistic is t = ??? (±±0.001)

Yes

No

Answer 1